MedTrace Logo

Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial

NCT00718679 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-02-11

No results posted yet for this study

Summary

This study is placebo controlled, double blind, randomised, two arm dose escalation of a new product for specific immunotherapy in cat allergic patients

Conditions

  • Allergy to Cat Dander

Interventions

DRUG

IVN201

Intralymphativ injection of the study drug

DRUG

Placebo

Sponsors & Collaborators

  • ImVision GmbH, Hannover

    collaborator UNKNOWN

  • University of Zurich

    lead OTHER

Principal Investigators

  • Gabriela Senti, MD · UniversitaetsSpital Zuerich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00718679 on ClinicalTrials.gov